Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age \>16 weeks (determined by LMP and fundal height)- if there is discordance between the two, the more conservative estimate (i.e. lower) will be used, to prevent accidental exposure of a 1st trimester fetus~* Normal fetal heart beat detected by Doppler~* Presence of asexual P. vivax parasitemia ≤ 50,000 parasites/microliter (thick smear)~* Willing to sign or thumb print informed consent~* Willing to return for scheduled follow up visits for treatment and observation until delivery~* Willing to deliver in health facility~Exclusion Criteria:~* Pregnancy \< 16 weeks~* Microscopically confirmed P. falciparum or mixed infection/ parasitemia (P. vivax and another species of Plasmodium, i.e. P. vivax, P. ovale, or P. malariae)~* History of allergy or hypersensitivity to interventional drugs~* Exposure to antimalarial drugs and other drugs with antimalarial activity within the past 2 months, as determined by history from the woman (quinine, mefloquine, or artemisinin derivatives, including AL and MA)~* Patients taking drugs with possible interaction with study drugs (ie. warfarin, digoxin)~* History or family history of epilepsy or psychiatric disorder~* Presence of signs and symptoms of severe malaria, severe illness, or danger signs~* Hemoglobin \< 7 g/dl~* Inability to tolerate oral medication (repeated vomiting, impairment of consciousness).~* History of chronic disease including diabetes, renal failure, hepatic failure, heart disease requiring anti-arrhythmic drugs or warfarin, HIV/ AIDS, known hemoglobinopathy~* Participant's inability to return for follow up visits~* Age \<15 years

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mefloquine- Artesunate (Type: EXPERIMENTAL): Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
- Artemether-Lumefantrine (Type: EXPERIMENTAL): Artemether-Lumefantrine, Lumet, Cipla 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
- Chloroquine (Type: ACTIVE_COMPARATOR): Chloroquine (Farmaguinhos, Brazil): Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).